Report Highlights

U.S. Thyroid Testing: Market Overview

The United States is the largest national market for thyroid testing, with 2024 revenues estimated at USD 1.9 billion across immunoassay reagents, analyzers, and reference laboratory services. Thyroid-stimulating hormone measurement is among the most frequently ordered endocrine tests in the country, making the market high-volume and reagent-driven rather than device-driven. Pricing is set largely by payer fee schedules and laboratory contracts, which differs sharply from the global norm.

Testing is concentrated in CLIA-certified clinical laboratories, with Quest Diagnostics and Labcorp handling a substantial share of outpatient volume. Hospital laboratories run high-throughput chemiluminescence platforms from Abbott, Roche, and Siemens Healthineers. Thyroid antibody testing for autoimmune disease, including TPO and TRAb assays, forms a faster-growing layer on top of routine TSH monitoring.

Growth Drivers in U.S. Thyroid Testing

The U.S. population aged 65 and older exceeds 60 million, and thyroid dysfunction, particularly subclinical hypothyroidism, rises with age. Medicare Part B covers thyroid function tests when medically necessary, and older patients on hormone replacement require periodic TSH monitoring throughout their treatment.

Levothyroxine is one of the most dispensed prescription drugs in the United States, creating a recurring testing base of tens of millions of patients. The American Thyroid Association estimates that roughly one in eight American women will develop a thyroid disorder in her lifetime, sustaining demand across gynecology and obstetric pathways.

Market Restraints and Entry Barriers

Entrants must clear FDA premarket review, typically a 510(k) for TSH assays, and secure CLIA categorization before laboratories can adopt a new platform. FDA's 2024 Laboratory Developed Test rule was vacated by a federal court in March 2025, which keeps laboratory-built assays competing directly with commercial kits.

Roche, Abbott, and Siemens Healthineers hold installed-base lock-in through reagent rental agreements that bundle analyzers with multi-year consumable contracts. Medicare Clinical Laboratory Fee Schedule rates, subject to PAMA market-based reporting, compress reimbursement for routine TSH and leave little margin for new entrants offering discounts.

Market Opportunities in U.S. Thyroid Testing

CLIA-waived TSH point-of-care testing offers an entry route into retail clinic networks, urgent care, and telehealth-linked home collection. Analyst estimates place the addressable point-of-care share of routine TSH volume at roughly USD 250 million by 2028, concentrated in pharmacy-based and primary care settings.

Thyroid antibody panels and thyroglobulin monitoring after cancer treatment are growing faster than routine TSH testing. Newborn screening for congenital hypothyroidism is mandated across all 50 states, creating recurring state-level reference laboratory contracts for suppliers with high-throughput neonatal assays.

Regulatory and Policy Environment

Thyroid assays are regulated as clinical chemistry devices under 21 CFR Part 862 at FDA, while laboratories performing testing must comply with the Clinical Laboratory Improvement Amendments of 1988 under 42 CFR Part 493. CMS administers CLIA certification, and FDA's 510(k) review targets a 90-day decision clock excluding time for additional information requests.

Reimbursement is governed by the Clinical Laboratory Fee Schedule under Section 216 of the Protecting Access to Medicare Act of 2014, which requires applicable laboratories to report private payer rates. The USPSTF screening recommendations and state newborn screening programs, coordinated through HRSA's Recommended Uniform Screening Panel, shape where testing volume is required.

Long-Term Outlook for U.S. Thyroid Testing

By 2032, the U.S. thyroid test market is projected to reach USD 2.85 billion, driven by antibody testing, chronic monitoring, and a gradual shift of routine TSH volume toward waived point-of-care platforms. Growth will be steadier than the global average, supported by an aging base of treated patients.

The principal risks are continued Medicare rate pressure, further consolidation among national reference laboratories, and renewed regulatory action on laboratory-developed tests. Suppliers that secure waived assays and align with state newborn screening programs will hold the strongest positions through the forecast period.

Market at a Glance

Leading Market Participants

• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• Beckman Coulter
• Ortho Clinical Diagnostics
• Bio-Rad Laboratories
• Quest Diagnostics
• Labcorp
• Thermo Fisher Scientific
• Mayo Clinic Laboratories